On July 28, 2026, ClinicalTrials.gov listed an update for the ERADICATE study, registered as NCT04484818. The trial evaluates the addition of darolutamide to hormonal therapy, including androgen deprivation therapy such as triptorelin, in men treated surgically for high-risk prostate cancer. The study is a Phase 3 trial and its current status is listed as active, not recruiting.
The trial title, "Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study," describes the combination approach under investigation. No outcome data or results have been reported in this update. The listing reflects only the trial's phase and enrollment status as of the stated date.
Triptorelin is used within the ADT component of this regimen as part of standard hormonal therapy following surgery. This update does not indicate whether the combination therapy is effective or safe, only that the trial has moved into an active, non-recruiting phase. Further updates would be needed to report any efficacy or safety findings.
Readers interested in triptorelin's approved uses and general background can consult the compound overview for additional context.